Critical review of cancer risk associated with angiotensin receptor blocker therapy

References

• Committee for Medicinal Products for Human Use, European Medicines AgencyReflection Paper on Benefit-Risk Assessment Methods in the Context of the Evaluation of Marketing Authorization Applications of Medicinal Products for Human UseLondonEuropean Medicines Agency2008 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069634.pdfAccessed March 19, 2008
   Google Scholar
• HughesDABayoumiAMPirmohamedMCurrent assessment of risk-benefit by regulators: is it time to introduce decision analyses?Clin Pharmacol Ther200782212312717632534
   PubMed Web of Science ®Google Scholar
• TurnbullFBlood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• LawMRMorrisJKWaldNJUse of blood pressure lowering drugs in the prevention of cardiovascular disease: meta analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ2009338b166519454737
   PubMed Web of Science ®Google Scholar
• WrightJMMusiniVMFirst-line drugs for hypertensionCochrane Database Syst Rev20093CD00184119588327
   PubMedGoogle Scholar
• HeinonenOPShapiroSTuominenLTurunenMIReserpine use in relation to breast cancerLancet1974278826756774142957
   PubMed Web of Science ®Google Scholar
• GrossmanEMesserliFHGoldbourtUDoes diuretic therapy increase the risk of renal cell carcinoma?Am J Cardiol19998371090109310190526
   PubMed Web of Science ®Google Scholar
• McLaughlinJKChowWHMandelJSInternational renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertensionInt J Cancer19956322162217591207
   PubMed Web of Science ®Google Scholar
• PahorMGuralnikJMFerrucciLCalcium-channel blockade and incidence of cancer in aged populationsLancet199634890264934978757150
   PubMed Web of Science ®Google Scholar
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractionsThe SOLVD InvestigattorsN Engl J Med1992327106856911463530
   PubMed Web of Science ®Google Scholar
• ColemanCIBakerWLKlugerJWhiteCMAntihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta analysis of randomized controlled trialsJ Hypertens200826462262918327066
   PubMed Web of Science ®Google Scholar
• GrossmanEMesserliFHLong-term safety of antihypertensive therapyProg Cardiovasc Dis2006491162516867847
   PubMed Web of Science ®Google Scholar
• GrossmanEMesserliFHGoldbourtUAntihypertensive therapy and the risk of malignanciesEur Heart J200122151343135211465967
   PubMed Web of Science ®Google Scholar
• SipahiIDebanneSMRowlandDYSimonDIFangJCAngiotensin-receptor blockade and risk of cancer: meta analysis of randomised controlled trialsLancet Oncol201011762763620542468
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• JuliusSNesbittSDEganBMFeasibility of treating pre-hypertension with an angiotensin-receptor blockerN Engl J Med2006354161685169716537662
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsYusufSTeoKAndersonCEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• BangaloreSKumarSKjeldsenSEAntihypertensive drugs and risk of cancer: network meta analyses and trial sequential analyses of 324,168 participants from randomised trialsLancet Oncol2011121658221123111
   PubMed Web of Science ®Google Scholar
• BerlTHunsickerLGLewisJBCardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyAnn Intern Med2003138754254912667024
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• DisertoriMLatiniRBarleraSValsartan for prevention of recurrent atrial fibrillationN Engl J Med2009360161606161719369667
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• HouFFXieDZhangXRenoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiencyJ Am Soc Nephrol20071861889189817494885
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• KasanukiHHagiwaraNHosodaSAngiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)Eur Heart J200930101203121219346521
   PubMed Web of Science ®Google Scholar
• LindholmLHPerssonMAlaupovicPCarlbergBSvenssonASamuelssonOMetabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)J Hypertens20032181563157412872052
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• MochizukiSDahlofBShimizuMValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyLancet200736995711431143917467513
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJGomisRAndersenSArnerPThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• SawadaTYamadaHDahlofBMatsubaraHEffects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART StudyEur Heart J200930202461246919723695
   PubMed Web of Science ®Google Scholar
• SuzukiHKannoYEffects of candesartan on cardiovascular outcomes in Japanese hypertensive patientsHypertens Res200528430731416138560
   PubMed Web of Science ®Google Scholar
• SuzukiHKannoYSugaharaSEffect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trialAm J Kidney Dis200852350150618653268
   PubMed Web of Science ®Google Scholar
• ZileMRGaaschWHAnandISMode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trialCirculation2010121121393140520231531
   PubMed Web of Science ®Google Scholar
• TeoKKSleightPGaoPEffects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individualsJ Hypertens201129462363521358417
   PubMed Web of Science ®Google Scholar
• McMurrayJJHolmanRRRuttenGEHMCaliffRMEffect of Valsartan on the Incidence of Diabetes and Cardiovascular EventsN Engl J Med2010362161477149020228403
   PubMed Web of Science ®Google Scholar
• YusufSHealeyJSPogueJIrbesartan in Patients with Atrial FibrillationN Engl J Med20113641092893821388310
   PubMed Web of Science ®Google Scholar
• ChaturvediNPortaMKleinREffect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsLancet200837296471394140218823656
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• SjolieAKKleinRPortaMEffect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialLancet200837296471385139318823658
   PubMed Web of Science ®Google Scholar
• GrossmanEGoldbourtUMeta analyses of antihypertensive therapy: Are some of them misleading?Curr Hypertens Rep20013538138611551371
   PubMedGoogle Scholar
• LeverAFHoleDJGillisCRDo inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?Lancet199835291231791849683206
   PubMed Web of Science ®Google Scholar
• RosenthalTGavrasIAngiotensin inhibition and malignancies: a reviewJ Hum Hypertens2009231062363519339998
   PubMed Web of Science ®Google Scholar
• DeshayesFNahmiasCAngiotensin receptors: a new role in cancer?Trends Endocrinol Metab200516729329916061390
   PubMed Web of Science ®Google Scholar
• WillisLMEl-RemessyABSomanathPRDeremerDLFaganSCAngiotensin receptor blockers and angiogenesis: clinical and experimental evidenceClin Sci (Lond)2011120830731921488224
   PubMed Web of Science ®Google Scholar
• ImaiNHashimotoTKiharaMRoles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesisLab Invest200787218919817318197
   PubMed Web of Science ®Google Scholar
• KosugiMMiyajimaAKikuchiEHoriguchiYMuraiMAngiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancerClin Cancer Res20061292888289316675585
   PubMed Web of Science ®Google Scholar
• KosakaTMiyajimaATakayamaEAngiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancerProstate2007671414917044086
   PubMed Web of Science ®Google Scholar
• OtakeAHMattarALFreitasHCInhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanomaCancer Chemother Pharmacol2010661798719771429
   PubMed Web of Science ®Google Scholar
• KosakaTMiyajimaAShirotakeSEts-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancerProstate201070216216919760626
   PubMed Web of Science ®Google Scholar
• ClereNCorreIFaureSDeficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesisInt J Cancer2010127102279229120143398
   PubMed Web of Science ®Google Scholar
• WaltherTMenradAOrzechowskiHDSiemeisterGPaulMSchirnerMDifferential regulation of in vivo angiogenesis by angiotensin II receptorsFASEB J200317142061206714597675
   PubMed Web of Science ®Google Scholar
• ForderJPMunzenmaierDHGreeneASAngiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the ratAm J Physiol Heart Circ Physiol20052884H1989199615498820
   PubMed Web of Science ®Google Scholar
• KozakAErgulAEl-RemessyABCandesartan augments ischemia-induced proangiogenic state and results in sustained improvement after strokeStroke20094051870187619265050
   PubMed Web of Science ®Google Scholar
• BuckCDonnerACancer incidence in hypertensivesCancer1987597138613903815311
   PubMed Web of Science ®Google Scholar
• RaynorWJJrShekelleRBRossofAHMalizaCPaulOHigh blood pressure and 17-year cancer mortality in the Western Electric Health StudyAm J Epidemiol198111343713777211822
   PubMed Web of Science ®Google Scholar
• DyerARStamlerJBerksonDMLindbergHAStevensEHigh blood-pressure: a risk factor for cancer mortality?Lancet1975179151051105648728
   PubMed Web of Science ®Google Scholar
• KhawKTBarrett-ConnorESystolic blood pressure and cancer mortality in an elderly populationAm J Epidemiol198412045505586475925
   PubMed Web of Science ®Google Scholar
• HametPCancer and hypertension. An unresolved issueHypertension19962833213248794810
   PubMed Web of Science ®Google Scholar
• WannametheeGShaperAGBlood pressure and cancer in middle-aged British menInt J Epidemiol199625122318666495
   PubMed Web of Science ®Google Scholar
• CalleEEThunMJObesity and cancerOncogene200423386365637815322511
   PubMed Web of Science ®Google Scholar
• KannelWBBrandNSkinnerJJJrDawberTRMcNamaraPMThe relation of adiposity to blood pressure and development of hypertension. The Framingham studyAnn Int Med196767148596028658
   PubMed Web of Science ®Google Scholar
• ChowWHGridleyGFraumeniJFJrJarvholmBObesity, hypertension, and the risk of kidney cancer in menN Engl J Med2000343181305131111058675
   PubMed Web of Science ®Google Scholar
• SwalesJDMeta analysis as a guide to clinical practiceJ Hypertens Suppl1993115S59638158435
   PubMedGoogle Scholar
• US Food and Drug Administration (FDA)FDA drug safety communication: ongoing safety review of the angiotensin receptor blockers and cancer [web page on the Internet]Rockville, MD2010 [updated February 6, 2011]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand/ucm218845.htmAccessed September 1, 2011
   Google Scholar